Amgen (AMGN) Convertible Debt (2009 - 2010)

Amgen (AMGN) posted quarterly Convertible Debt of $2.2 billion for Q1 2010, down 51.22% quarter-over-quarter from $4.5 billion in Q4 2009.

Amgen (AMGN) Convertible Debt (2009 - 2010) Analysis & Trends

Amgen's Convertible Debt history runs 2 years deep, the most recent figure standing at $2.2 billion for Q1 2010.

In Q1 2010, Convertible Debt changed N/A year-over-year to $2.2 billion; the TTM figure through Mar 2010 stood at $2.2 billion (changed N/A YoY), while the FY2009 annual figure was $4.5 billion, changed N/A from the prior year.
Convertible Debt for Q1 2010 stood at $2.2 billion, down from $4.5 billion in the prior quarter.
The five-year high for Convertible Debt was $4.5 billion in Q4 2009, with the low at $2.2 billion in Q1 2010.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.29 Bn	631.53 Bn	17.26 Bn
2	AbbVie	470.62 Bn	464.06 Bn	12.70 Bn
3	Merck	375.66 Bn	368.52 Bn	12.21 Bn
4	Novartis Ag	302.90 Bn	295.21 Bn	11.24 Bn
5	Astrazeneca	257.50 Bn	252.60 Bn	12.86 Bn
6	Amgen	237.19 Bn	223.20 Bn	7.24 Bn
7	Gilead Sciences	182.92 Bn	179.74 Bn	6.22 Bn
8	Pfizer	160.14 Bn	148.44 Bn	10.94 Bn
9	Gsk	106.08 Bn	101.91 Bn	8.24 Bn
10	Sanofi	55.22 Bn	47.84 Bn	10.79 Bn

Download Data